Charles River Laboratories International, Inc.
CRL
$291.76
$9.423.34%
NYSE
| 06/27/2026 | 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | |
|---|---|---|---|---|---|
| Net Income | -102.83% | -158.28% | -28.93% | -21.87% | -47.52% |
| Total Depreciation and Amortization | -17.56% | -14.64% | 91.95% | -83.94% | -7.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 88.56% | 43.11% | -16.72% | 569.99% | 221.41% |
| Change in Net Operating Assets | -101.58% | -8,342.35% | 115.97% | -107.20% | 198.54% |
| Cash from Operations | -12.16% | -76.08% | -7.43% | -15.08% | 5.72% |
| Capital Expenditure | 11.88% | 5.76% | -17.63% | 8.11% | 10.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 244.57% | -- | -- | -- |
| Other Investing Activities | 344.15% | -95.41% | -690.37% | -89.17% | 87.92% |
| Cash from Investing | 175.25% | -796.78% | -21.95% | -58.02% | 39.65% |
| Total Debt Issued | -35.51% | 119.16% | 49.50% | -54.37% | 24.23% |
| Total Debt Repaid | 47.14% | -138.08% | -17.56% | 23.01% | -6.25% |
| Issuance of Common Stock | 39,600.00% | -- | -7.42% | -99.74% | -99.88% |
| Repurchase of Common Stock | -1,472.31% | 41.02% | 22.58% | 99.91% | 17.52% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 57.54% | 89.55% | 70.61% | 53.74% | -21.76% |
| Cash from Financing | 27.44% | 430.14% | 31.65% | 26.46% | 20.62% |
| Foreign Exchange rate Adjustments | -106.16% | -76.30% | 129.21% | -139.38% | 479.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 190.19% | -168.03% | 211.65% | -20.09% | 70.17% |